X-linked hyper-IgM (X-HIM) syndrome is a primary immunodeficiency disease characterized by defects in both cellular and humoral immunity. X-HIM is caused by mutations in the gene for CD40 ligand (CD40L), a T cell membrane protein that mediates T cell-dependent immune functions. We report the case of a 6-year-old male with X-HIM due to an intronic mutation resulting in aberrant CD40L RNA splicing and absence of detectable CD40L protein. The patient had a history of multiple infectious complications and chronic neutropenia requiring treatment with recombinant granulocyte colony-stimulating factor, and underwent allogeneic bone marrow transplantation from an HLA-matched sibling donor. Following successful engraftment, T cell CD40L expression and immunoglobulin isotype switching were reconstituted and neutropenia resolved. Allogeneic bone marrow transplantation can correct neutropenia and reconstitute immune function in X-HIM.
X-linked hyper-IgM syndrome (X-HIM) is a rare immunodeficiency disease characterized by hypogammaglobulinemia, defective antibody function and cell-mediated immune dysfunction. 1 The disease is caused by mutations of the gene for CD40 ligand (CD40L), an inducible membrane protein that is transiently expressed on CD4 + T cells after activation. [2] [3] [4] [5] [6] CD40L binds to the CD40 receptor expressed on multiple cell types including B cells, monocytes/ macrophages, and epithelial cells, triggering diverse CD40-mediated effector functions. 7 Patients with X-HIM characteristically have very low or absent serum levels of IgG, IgA and IgE, with normal or elevated IgM levels. This pattern of hypogammaglobulinemia is attributable to the failure of CD40L-dependent B cell immunoglobulin isotype switching, and results in susceptibility to infection with Correspondence: Dr PR Scholl, Children's Memorial Institute for Education and Research, Mailbox No. 222, 2300 Children's Plaza, Chicago, IL 60614, USA Received 29 May 1998; accepted 24 July 1998 common bacterial and viral pathogens. Other complications of X-HIM include infection with opportunistic pathogens, especially Pneumocystis carinii and Cryptosporidium; hepatobiliary disease, including cholangitis, hepatic cirrhosis, and tumors of the liver, biliary tree and pancreas; and episodic or chronic neutropenia, often associated with oral ulceration.
The recommended treatment for X-HIM includes regular intravenous immunoglobulin infusions and antimicrobial prophylaxis against Pneumocystis carinii infection. 8, 9 Neutropenia in X-HIM has been treated successfully with increased doses of intravenous immunoglobulin and/or recombinant granulocyte colony-stimulating factor (G-CSF). [8] [9] [10] Bone marrow transplantation for X-HIM has been reported in a very few cases.
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We describe a 6-year-old boy with X-HIM, a history of numerous hospitalizations for infectious complications, and chronic neutropenia requiring prolonged G-CSF therapy. Allogeneic bone marrow transplantation from an HLAmatched sibling donor was performed. Successful engraftment was followed by reconstitution of T celldependent immunoglobulin synthesis and resolution of neutropenia.
Materials and methods

CD40L protein expression
The induction of CD40L expression with phorbol ester and calcium ionophore and flow cytometric analysis was performed as described previously.
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CD40L mutational analysis
RNA and genomic DNA were extracted from peripheral blood mononuclear cells using TriZol (Gibco, Gaithersburg, MD, USA) according to the manufacturer's protocol. For RT-PCR, RNA was extracted from phorbol ester and calcium ionophore-stimulated cells and was reverse transcribed using MMLV-RT (Stratagene, La Jolla, CA, USA) and random hexanucleotide primers. PCR amplification of CD40L cDNA and genomic DNA was performed as described 15 on a Perkin Elmer (Norwalk, CT, USA) 9600 thermal cycler using Taq polymerase. CD40L cDNA was amplified with primers complementary to the 5Ј and 3Ј untranslated regions. A fragment of CD40L genomic DNA was amplified using primers complementary to the 3Ј end of intron 2 (sense primer) and the 3Ј end of exon 4 (antisense primer) (provided by Dr R Fuleihan, Yale University Medical School). All results were confirmed by sequencing multiple clones from independent amplification reactions.
PCR products were excised from agarose gels and cloned into pGEM(T) (Promega, Madison, WI, USA). cDNA was sequenced along both strands with universal T7 and SP6 primers using Amplitaq Polymerase FS and dye terminators (Perkin Elmer). cDNA was also sequenced manually using Sequenase (USB, Cleveland, OH, USA). Amplified genomic DNA was either cloned into pGEM(T) for sequencing as above or sequenced directly after purification. The sequencing reactions were run on an ABI Prism 377 automated sequencer and the results analyzed with the Sequence Navigator software package (ABI Perkin Elmer). Nucleotides are numbered according to GenBank accession number L07414.
Case report
The patient is a Hispanic male who first presented in 1992 at the age of 17 months with a history of diarrhea, poor weight gain, recurrent respiratory infections and oral ulcers. Three male siblings had died in Mexico between the ages of 9 and 15 months and had had similar symptoms. Two maternal uncles had died in infancy of undetermined causes. The patient's laboratory studies demonstrated hypogammaglobulinemia with very low IgG and elevated IgM levels; specific antibody titer to tetanus antigen was below the protective range despite a history of appropriate immunization (Table 1) . Delayed type hypersensitivity to Candida antigen was present. The peripheral T and B lymphocyte numbers and the lymphocyte proliferative responses to mitogens were normal. A clinical diagnosis of hyper-IgM syndrome was made.
The patient was treated with intravenous immunoglobulin infusions to maintain normal serum IgG levels and intermittently with co-trimoxazole (5 mg/kg/day 3 days weekly) for prophylaxis against Pneumocystis carinii infection. Once intravenous immunoglobulin treatment had been commenced, IgM levels normalized and IgA became undetectable (Table 1) . During the 5 year period following his initial presentation the patient continued to experience numerous medical problems. Bilateral vocal cord paresis was diagnosed and required a permanent tracheostomy. There were recurrent episodes of pneumonia necessitating intravenous antibiotic therapy. At the age of 4 years (prior to treatment with co-trimoxazole) the patient developed severe neutropenia. A bone marrow aspirate demonstrated maturational arrest of granulocyte precursors, and treatment with G-CSF (10 g/kg/day) was commenced. Three months later he developed severe hip pain. Radiological studies and a bone biopsy were suggestive of bone infarction. G-CSF therapy was discontinued. Fifteen months later because of severe oral ulceration, esophageal stricture, dysphagia, poor oral intake and weight loss, a gastrostomy tube was placed. G-CSF was restarted at a lower dose (5 g/kg/day) and continued over the next 17 months, during which the patient continued to be intermittently neutropenic ( Figure 1) . Analysis of CD40L expression by the patient's in vitro activated peripheral blood CD4 + T cells was first performed in 1995, with the results shown in Figure 2 . In contrast to normal control subjects, the patient's CD4 + T cells expressed no detectable CD40L after in vitro activation.
Analysis of his sister's CD4
+ T cells demonstrated a bimodal pattern of CD40L expression with distinct populations of CD40L
− and CD40L + cells, as has been observed in some obligate carriers of X-HIM. [14] [15] [16] Sequence analysis of the patient's CD40L cDNA revealed a 63 bp deletion coinciding with the sequence encoded by exon 4 of the CD40L gene, suggesting a splicing mutation (data not shown). Sequencing of a PCR-amplified genomic DNA 17 Three other intronic mutations resulting in the same 63 bp exon 4 cDNA deletion have previously been reported to cause X-HIM. 15, 18, 19 The patient's 17-year-old sister was also tested and found to be heterozygous for the intron 3 splice acceptor site mutation (Figure 2) .
Because of the frequent occurrence of infectious complications that occurred despite intravenous immunoglobulin therapy, the chronicity of neutropenia requiring long-term G-CSF therapy, and the availability of an HLA-matched sibling donor, the patient's sister, the option of bone marrow transplantation was discussed with the family and consent to this procedure was obtained. The patient was conditioned with total body irradiation (150 cGy twice a day × 8 doses) and cyclophosphamide (500 mg/m 2 /dose i.v. three times a day × 9 doses). The choice of this regimen rather than a busulfan containing regimen was based on the known difficulties encountered in maintaining adequate busulfan levels in pediatric patients to produce ablation without unacceptable toxicity. 20, 21 Transplantation was performed with 1.7 × 10 8 mononuclear cells/5.6 × 10 6 CD34 + cells per kg body weight. Prophylaxis for graft-versus-host disease was given including cyclosporin A (4 mg/kg/day i.v. divided every 12 h) and short-course methotrexate (15 mg/m 2 i.v. on day +1, 10 mg/m 2 on days +3 and +6). Stage I, grade I acute skin GVHD developed on day +18 and subsequently resolved with steroid treatment (prednisone 2 mg/kg for 4 days followed by a slow taper over the next 2 months). Intravenous immunoglobulin (250 mg/kg once a month) and pentamidine (4 mg/kg i.v. once a month) were given for 6 months after transplantation and then discontinued. G-CSF was given for 13 days starting 7 days after transplantation.
WBC engraftment occurred on day +11 and the patient was discharged home on day +13. The hospital course was complicated by mild mucositis, treated with supportive care and morphine by PCA, and by a Streptococcus mitis central line infection which resolved with appropriate antibiotic therapy. One hundred days after transplantation, restriction fragment polymorphism analysis of genomic DNA isolated from peripheral blood mononuclear cells demonstrated chimerism with Ͼ95% donor origin cells. As shown in Table 1 , levels of IgG, IgA and IgM 6 months after transplantation were within or above normal ranges. In vitro lymphocyte responses to mitogens were mildly diminished (data not shown). Flow cytometric analysis demonstrated that approximately 60% of CD4 + T cells expressed CD40L (Figure 2 ). The absolute neutrophil count remained within or above the normal range 10 months after transplantation (Figure 1 ). Sequence analysis of PCR-amplified CD40L genomic DNA demonstrated the presence of both normal and mutated sequence at the intron 3-exon 4 junction (Figure 2 ).
Discussion
The recommended management of X-HIM includes regular intravenous immunoglobulin infusions, antimicrobial prophylaxis against Pneumocystis carinii infection, and careful monitoring for complications. Currently, allogeneic stem cell transplantation is the only treatment alternative that offers the prospect of immune reconstitution. In the single detailed report of successful bone marrow transplantation for X-HIM published to date, the procedure was undertaken in infancy because of a history of poor outcome in affected relatives of the proband. 13 In the present case, the decision to undertake bone marrow transplantation was based on the unusually severe course of the patient's disease including recurrent pneumonia requiring multiple hospitalizations, chronic neutropenia, severe oral ulceration, esophageal stricture requiring a gastrostomy, and because of the availability of an HLA-matched sibling donor.
Neutropenia is a common complication of X-HIM with a frequency estimated at 37 and 68% in two recent studies. 1, 9 The specific cause is usually unknown. Successful use of G-CSF to treat neutropenia in X-HIM was reported in 1994. 10 The safety of long-term G-CSF therapy is not known; in our patient severe bone pain accompanied by evidence of bone necrosis developed during G-CSF treatment and limited its use. The resolution of neutropenia following bone marrow transplantation in the present case indicates that it is amenable to correction by this procedure.
The decision to offer bone marrow transplantation for patients with X-HIM needs to be made after a careful weighing of risks and benefits for each individual case. Potential benefits of the procedure include immune reconstitution, correction of chronic neutropenia, and prevention of other complications of the disease. These must be balanced against the risks and cost of the procedure. Although the data of Levy et al 1 suggest a poor prognosis for conservatively managed X-HIM, for some patients in whom the disease follows a relatively benign course, the risks of bone marrow transplantation may well outweigh the potential benefits. Nevertheless, the present case and previous reports [11] [12] [13] demonstrate the effectiveness of bone marrow transplantation in correcting the underlying defect of X-HIM and suggest that this form of treatment should be considered in severely affected patients when a matched sibling donor is available.
